Suppr超能文献

用新兴疗法挑战青光眼:针对视力“隐形窃贼”的进展概述

Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.

作者信息

Sarkis Solange, Chamard Chloé, Johansen Bianca, Daien Vincent, Michon Frederic

机构信息

Institute for Neurosciences of Montpellier, Univ Montpellier, Institut national de la santé et de la recherche médicale (INSERM), Montpellier, France.

Laboratoires Théa, Clermont-Ferrand, France.

出版信息

Front Med (Lausanne). 2025 Mar 26;12:1527319. doi: 10.3389/fmed.2025.1527319. eCollection 2025.

Abstract

Glaucoma, a leading cause of irreversible blindness, represents a significant challenge in ophthalmology. This review examines recent advancements in glaucoma treatment, focusing on innovative medications and creative strategies. While new agents offer promising methods for lowering intraocular pressure (IOP), they also pose challenges related to efficacy and side effects. Alongside IOP reduction, emerging neuroprotective approaches are being explored to safeguard retinal ganglion cells (RGCs) from glaucoma-induced damage. The review also evaluates the potential of novel drug delivery systems, such as biodegradable implants and nanoparticles, to enhance treatment effectiveness and patient adherence. Additionally, it highlights the role of personalized medicine in identifying new biomarkers and customizing therapies based on individual genetic and environmental factors.

摘要

青光眼是不可逆性失明的主要原因,是眼科领域的一项重大挑战。本综述探讨了青光眼治疗的最新进展,重点关注创新药物和创新策略。虽然新药物为降低眼压提供了有前景的方法,但它们也带来了与疗效和副作用相关的挑战。除了降低眼压外,正在探索新兴的神经保护方法,以保护视网膜神经节细胞免受青光眼所致损伤。本综述还评估了新型药物递送系统(如可生物降解植入物和纳米颗粒)提高治疗效果和患者依从性的潜力。此外,它强调了个性化医疗在识别新生物标志物以及根据个体遗传和环境因素定制治疗方案方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a56/11979169/1317b2958d96/fmed-12-1527319-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验